The experiment involved 18 specific-pathogen-free male C57BL/6 mice aged 2–3 weeks. After a week of acclimatization, the mice were assigned to three groups of six: an untreated control group, an antibiotic group and a fecal microbiota transplantation group. The latter two groups received a broad-spectrum oral antibiotic cocktail containing ampicillin, gentamicin and vancomycin twice daily for eight consecutive days. Antibiotic-only mice then received sterile phosphate-buffered saline by gavage for four days, while transplantation recipients received a fecal microbiota suspension by the same route once daily for that period.

The donor suspension was prepared from pooled feces collected from five healthy, untreated 8-week-old adult C57BL/6J mice. It was administered at 0.1 mL per mouse and used within two hours of preparation. The investigators did not sequence the donor inoculum, so the analyses could not directly establish the origin or engraftment rate of specific donor strains. They also did not include a comparison group receiving age-matched juvenile donor material.

Microbial composition was assessed by sequencing the V3–V4 regions of the 16S rRNA gene, with six mice per group. Antibiotic exposure sharply reduced the Chao1 richness and Shannon diversity indices compared with controls, with P values below 0.001 for both measures. After transplantation, the Shannon index recovered to a level that did not differ significantly from the control group, while the Chao1 index showed a partial, statistically significant improvement over the antibiotic group. Principal coordinate analysis based on unweighted UniFrac distance showed distinct community structures among the three groups, with an Adonis R-squared value of 0.582 and P=0.001.

The transplanted microbiota was not simply a return to the pre-antibiotic juvenile composition. Antibiotic-treated mice showed marked depletion of taxa including Muribaculaceae and Lachnospiraceae_NK4A136_group and a substantial relative expansion of Bacteroides. Fecal microbiota transplantation was associated with reduced Bacteroides abundance and recovery of Muribaculaceae to levels not significantly different from controls. It also increased the relative abundance of low-abundance taxa and produced biomarker profiles that included Parabacteroides, Lachnoclostridium, Tannerellaceae and members of Desulfobacterota. The investigators characterized these findings as a distinct community state, although they could not confirm that the detected taxa originated from the adult donor because the inoculum itself was not sequenced.

Colonic tissue was collected on day 13 from three randomly selected mice per group for molecular analyses. Quantitative reverse-transcription polymerase chain reaction showed that antibiotics increased colonic transcript levels of IL-10, IL-17 and IL-22 relative to controls, with P values of 0.01 or lower. Transplantation was associated with lower IL-17 and IL-22 expression than antibiotic treatment alone, with P=0.036 and P=0.024, respectively. IL-10 expression in the transplantation group did not differ significantly from the antibiotic group, at P=0.068, and remained higher than in controls, at P=0.014.

Western blot analysis provided a partial measure of changes in the TLR4/MyD88 signaling axis. Antibiotic-treated mice had higher colonic TLR4 and MyD88 protein abundance than controls, with P values below 0.001. After transplantation, TLR4 abundance was significantly lower than in the antibiotic group, at P=0.011. MyD88 showed a downward trend but did not differ significantly from the antibiotic-only group. These measurements therefore associated fecal microbiota transplantation with attenuation of TLR4 expression and IL-17 and IL-22 transcription, rather than demonstrating a complete normalization of the pathway or the immune state.

Several limitations constrain the findings. The molecular endpoints were based on three mice per group, limiting the study’s ability to detect smaller differences in immune responses. Quantitative body-weight and food-intake data were not systematically recorded, and intestinal barrier function and tissue architecture were not assessed. The study also lacked luminal lipopolysaccharide and short-chain fatty acid measurements, direct sequencing of the pooled donor material, and an age-matched donor comparison. The findings consequently establish changes in mouse gut microbial composition and selected colonic immune markers over a short follow-up; they do not demonstrate a human clinical benefit, long-term stability of the transplanted community or restoration of mucosal homeostasis.

Overall, the mouse experiment indicates that a four-day course of adult-sourced fecal microbiota transplantation following early-life antibiotic exposure was associated with a partly restored microbial diversity index, suppression of antibiotic-associated Bacteroides expansion, a distinct taxonomic profile and lower selected intestinal immune markers. The authors said the results warrant further investigation of donor-age effects on microbial and mucosal immune recovery, while the absence of donor sequencing, a juvenile-donor comparator, functional barrier assays and a larger molecular sample limits stronger mechanistic conclusions.

Subject of Research: Effects of adult-sourced fecal microbiota transplantation on antibiotic-disrupted gut microbiota and colonic immune markers in juvenile mice

Article Title: Adult-sourced fecal microbiota transplantation ameliorates early-life antibiotic-induced intestinal immune stress in juvenile mice associated with the modulation of the TLR4/MyD88 signaling pathway

Article References: Qian, X., Shen, Y., Luo, X., Zhang, S., Wang, L., He, H., & Wang, B. (2026). Adult-sourced fecal microbiota transplantation ameliorates early-life antibiotic-induced intestinal immune stress in juvenile mice associated with the modulation of the TLR4/MyD88 signaling pathway. PLOS One, 21(10), e0359634. https://doi.org/10.1371/journal.pone.0359634

Image Credits: AI Generated

DOI: 10.1371/journal.pone.0359634

Keywords: fecal microbiota transplantation, early-life antibiotics, juvenile mice, gut microbiota, TLR4, MyD88, IL-17, IL-22, IL-10, 16S rRNA sequencing, Adult-sourced, fecal

The central discovery concerns fucosylation, the attachment of fucose sugars to mucin 2, or MUC2, the gel-forming glycoprotein that constitutes the bulk of the colonic mucus layer. Fucose residues added to MUC2 are not cosmetic. They alter the mucus matrix in ways that support its integrity and its interactions with the microbial community. In colitis, this fucosylation is lost, and the mucus barrier weakens, leaving the epithelial surface exposed. The new study shows that the flagellin of L. 3–1-57, the protein that forms the propeller-like appendage of the bacterium, can reverse this deficit through a defined immunological cascade.

The clinical foundation of the work rests on two cohorts of human participants. Compared with healthy controls and with patients whose ulcerative colitis was in remission, patients with active disease showed reduced abundance of L. 3–1-57 in their gut microbiota. The depletion was not random. The lower the abundance of the bacterium, the more severe the disease, an inverse correlation that held across the study population. This pattern suggests that L. 3–1-57 is not merely a passive bystander in colitis but a component of the microbial community whose presence tracks with mucosal health.

To test whether the relationship is causal, the team turned to mouse models of chemically induced colitis. Oral administration of live L. 3–1-57 attenuated intestinal inflammation and mucus barrier dysfunction. Purified flagellin from the bacterium, delivered without the living organism, achieved the same protection. The contrast with a well-known gut pathobiont was stark: flagellin from Escherichia coli exacerbated disease rather than relieving it. This strain-specific divergence is one of the most technically significant aspects of the study, because flagellins from different bacteria are structurally similar yet immunologically distinct, and the field has lacked a clear account of which commensal flagellins promote homeostasis rather than inflammation.

The mechanistic chain begins at Toll-like receptor 5, or TLR5, the innate immune receptor that recognizes bacterial flagellin. Using binding assays, the researchers demonstrated that L. 3–1-57 flagellin binds TLR5 with high affinity. Upon this engagement, dendritic cells, the antigen-presenting sentinels of the mucosal immune system, are activated to produce interleukin-23. Interleukin-23 in turn expands the population of group 3 innate lymphoid cells, or ILC3s, that produce interleukin-22. Interleukin-22 is a cytokine with well-documented effects on epithelial cells, and in this context it drives the expression of fucosyltransferase 2, the enzyme that catalyzes the α-1,2-linked fucosylation of MUC2. The restored fucosylation rebuilds the mucus matrix and closes the protective loop.

The team then dismantled the pathway piece by piece to confirm that each element is indispensable. Genetic ablation of Tlr5 in mice abolished the protective effect of the flagellin. Pharmacological inhibition of α-1,2-fucosylation eliminated the benefit even when the immune cascade was intact. Neutralization of interleukin-22 likewise erased the protection. These loss-of-function experiments establish that the TLR5–IL-23–IL-22 axis and the fucosylation it drives are not merely correlated with recovery but are required for it, a standard of mechanistic proof that many microbiome studies do not reach.

A further technical point addresses a common concern about flagellin-based therapies. Analysis of the gut microbiota by 16S rRNA amplicon sequencing showed that orally administered L. 3–1-57 flagellin did not induce broad restructuring of the microbial community. The protection, in other words, is not mediated by wholesale alteration of the microbiome but by a targeted immune and glycosylation pathway. Detection of His-tagged flagellin in colonic mucus confirmed that the protein reaches its site of action after oral delivery, and flow cytometric analysis documented the activation of dendritic cells in the colonic lamina propria and mesenteric lymph nodes.

The translational implications are threefold. First, the authors nominate L. 3–1-57 as a candidate next-generation probiotic, a living organism whose administration could restore a depleted protective community member. Second, the flagellin itself is proposed as a postbiotic therapy, a purified microbial product that delivers the benefit without the need for live bacteria, an approach that may offer more predictable dosing and safety. Third, the fecal depletion of L. 3–1-57 is suggested as a noninvasive auxiliary diagnostic biomarker, a measurable microbial signal that could complement clinical assessment of disease activity.

The study also contributes to a broader reevaluation of flagellin, a molecule long viewed with suspicion because of its role in inflammatory signaling. The new work demonstrates that flagellin is not a monolithic inflammatory trigger but a family of strain-specific immunomodulators whose effects depend on the producing organism. Flagellins from commensal bacteria are among the most potent modulators of intestinal immunity, yet their homeostatic functions have remained poorly defined. By identifying a commensal flagellin that promotes mucosal repair through a defined receptor-to-glycosylation pathway, the study provides a framework for distinguishing protective from harmful flagellins and for exploiting the protective ones therapeutically.

The work was supported by the National Natural Science Foundation of China and related funding programs, and was approved by the Ethics Committee of Tianjin Medical University General Hospital and the Tianjin Medical University Animal Care and Use Committee. The article is open access under a Creative Commons license, and the authors declare no competing interests. As with all preclinical microbiome research, the findings in mouse models and human associations will require further validation before clinical application, but the study establishes a complete mechanistic account of how a single commensal bacterium, acting through its flagellin and a defined immune axis, can rebuild the chemical architecture of the mucus barrier that colitis destroys.

,

Subject of Research: Commensal Lachnospiraceae bacterium mitigates colitis-induced mucin fucosylation deficits through ILC3/IL-22 axis

Article Title: Commensal Lachnospiraceae bacterium mitigates colitis-induced mucin fucosylation deficits through ILC3/IL-22 axis

Article References: Li, L., Jiang, J., Huang, Y., Yang, S., Wei, J., Dong, W., Zhong, W., Wang, B., Su, X., Cao, H., & Liu, T. (2026). Commensal Lachnospiraceae bacterium mitigates colitis-induced mucin fucosylation deficits through ILC3/IL-22 axis. Genome Biology. https://doi.org/10.1186/s13059-026-04304-7

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04304-7

Keywords: Commensal, Lachnospiraceae, bacterium, mitigates, colitis-induced, mucin, fucosylation, deficits, ILC3, IL-22, axis, scientific research

The study, led by Soledad Bouquez and Paola López Campos under the direction of corresponding author Maite Duhalde-Vega, examined mice fed a high-fat diet, a model that reliably reproduces the metabolic disturbances seen in human obesity. High-fat diets have long been implicated in metabolic disorders through mechanisms involving hyperuricemia, gut dysbiosis, and intestinal barrier dysfunction, but the precise chain of cause and effect has remained elusive. The Argentine team set out to determine whether pharmacological reduction of uric acid could interrupt that chain, and if so, by what molecular route.

The results were striking. Mice on the high-fat diet developed hyperuricemia, and their gut microbial communities shifted into a dysbiotic state characterized by an expansion of Proteobacteria, a phylum widely regarded as a microbial signature of epithelial dysfunction, along with altered ratios of Firmicutes to Bacteroidetes, a compositional change repeatedly linked to obesity and type 2 diabetes in human studies. At the same time, the animals’ intestines mounted an inflammatory program: levels of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α rose, while the anti-inflammatory mediators IL-10 and IL-22 declined. The team also detected increased serum lipopolysaccharide, or LPS, indicating that bacterial products were leaking across a compromised intestinal wall into the circulation, fueling systemic inflammation marked by elevated IL-6 and C-reactive protein.

When the researchers added allopurinol to the high-fat diet, the picture changed dramatically. The drug, which inhibits xanthine oxidase and thereby blocks uric acid production, normalized serum uric acid levels and, with them, restored microbial balance. The dysbiotic expansion of Proteobacteria receded, the Firmicutes/Bacteroidetes ratio shifted back toward a healthier profile, and the inflammatory storm in the gut subsided. Pro-inflammatory cytokines fell, protective IL-10 and IL-22 recovered, serum LPS dropped, and markers of intestinal barrier dysfunction improved. Equally important, the systemic inflammatory signs, elevated circulating IL-6 and CRP, diminished, suggesting that repairing the gut wall had consequences well beyond the intestine itself.

The most mechanistically revealing part of the study concerned tryptophan metabolism, an increasingly central theme in gut immunology. Tryptophan, an essential amino acid obtained from the diet, can be metabolized along several competing routes. One route, driven by the enzyme indoleamine 2,3-dioxygenase 1, or IDO1, shunts tryptophan toward catabolites that are generally associated with inflammation and immune suppression. Another route, carried out by gut bacteria, produces indoles, small molecules that serve as ligands for the aryl hydrocarbon receptor, or AhR, a transcription factor expressed in immune and epithelial cells. When AhR is activated by these microbial indoles, it promotes the production of interleukin-22, a cytokine that strengthens epithelial barrier function, stimulates antimicrobial peptide release, and maintains mucosal homeostasis.

In the high-fat diet mice, this protective circuitry was broken. The animals showed increased IDO1 activity and diminished indole production, tilting tryptophan metabolism away from AhR-activating ligands and toward inflammatory catabolites. Allopurinol treatment reversed this shift: IDO1 activity decreased and indole production was restored, replenishing the supply of microbial metabolites capable of engaging AhR. The result was a reinvigorated AhR–IL-22 axis, which the authors identified as the key mediator of the drug’s gut-protective effects. Prior work, including landmark studies showing that tryptophan catabolites from the microbiota engage AhR and balance mucosal reactivity via interleukin-22, had established the plausibility of this pathway; the new study ties it directly to uric acid metabolism.

To prove that the AhR–IL-22 axis was not merely correlated with the improvements but actually required for them, the team employed CH-223191, a selective pharmacological antagonist of the aryl hydrocarbon receptor. When AhR signaling was blocked in allopurinol-treated mice, the drug’s anti-inflammatory and barrier-protective effects were reversed. Cytokine profiles deteriorated, barrier function declined, and the benefits of uric acid reduction evaporated. This loss-of-function experiment provides functional evidence, not just associative data, that the AhR/IL-22 axis mediates gut protection in this model, a level of mechanistic rigor that strengthens the study’s therapeutic implications considerably.

The findings arrive amid growing interest in the interplay between purine metabolism, the microbiome, and intestinal health. Previous research has shown that hyperuricemia is associated with immune disorders and intestinal barrier dysfunction, that gut bacterial metabolism contributes to host purine homeostasis, and that hyperuricemia can influence tryptophan metabolism by inhibiting the transport proteins MRP4 and BCRP, which handle uric acid and metabolite trafficking across cell membranes. Uric acid itself is no innocent molecule: it was identified nearly two decades ago as a danger signal that alerts the immune system to dying cells, and elevated levels have been linked to metabolic syndrome through the activity of xanthine oxidoreductase. The new study weaves these threads into a coherent narrative in which dietary fat raises uric acid, uric acid disrupts the microbiome and tryptophan handling, and the resulting loss of AhR ligands starves the gut of the IL-22 signal it needs to maintain its barrier.

For clinicians, the appeal of the proposed strategy lies in its practicality. Allopurinol is inexpensive, generically available, and already used by millions of patients with gout and hyperuricemia, with a well-characterized safety profile. If the mechanisms observed in mice translate to humans, targeting hyperuricemia could offer a repurposable intervention for metabolic and inflammatory gut diseases, conditions that currently have limited therapeutic options. The authors suggest that uric acid modulation deserves consideration as a promising therapeutic strategy for these disorders, though they and outside observers alike will caution that mouse models of diet-induced disease do not always recapitulate human pathophysiology, and that clinical trials would be needed before uric acid lowering could be recommended for gut inflammation specifically.

The study also adds to a rapidly expanding literature on how diet reshapes the gut microbiome and, through it, systemic health. High-fat diets have been shown to alter microbial and metabolite profiles during obesity, to increase intestinal permeability, and to drive gut dysbiosis and inflammation that contribute to obesity-associated liver disease. Microbiota-targeted interventions, including washed microbiota transplantation in gout patients, have already shown hints of benefit on serum uric acid and intestinal barrier function in early pilot studies. What distinguishes the new work is its demonstration of a complete, mechanistically validated pathway, from dietary fat to uric acid to microbial composition to tryptophan-derived metabolites to AhR activation to IL-22-dependent barrier protection, with pharmacological confirmation at each critical node. That level of pathway resolution is rare, and it transforms a loose association between gout drugs and gut health into a testable therapeutic hypothesis.

The research, supported by grants from Argentina’s National Agency of Science and Technology and the Universidad de Buenos Aires, was conducted under approved animal care protocols and published as an original article in the Journal of Molecular Medicine. As obesity rates continue to climb worldwide and inflammatory bowel diseases grow more prevalent, the idea that a fifty-year-old gout medication might protect the gut by feeding the microbiome’s chemical conversation with the immune system is the kind of unexpected, cross-disciplinary insight that could reshape how clinicians think about the drugs they already prescribe. The next step will be determining whether lowering uric acid in people delivers the same tryptophan-centered, AhR-mediated protection that it does in mice, a question that the authors’ elegant mechanistic framework now makes far easier to ask.

Subject of Research: How anti-hyperuricemia therapy with allopurinol alleviates diet-induced gut inflammation in mice via the AhR–IL-22 signaling axis

Article Title: Anti-hyperuricemia therapy alleviates diet-induced gut inflammation via AhR-IL-22-signalling

Article References: Bouquez, S., Campos, P. L., Ottobre, M., & Duhalde-Vega, M. (2026). Anti-hyperuricemia therapy alleviates diet-induced gut inflammation via AhR-IL-22-signalling. Journal of Molecular Medicine, 104(1), Article 105. https://doi.org/10.1007/s00109-026-02713-6

Image Credits: AI Generated

DOI: 10.1007/s00109-026-02713-6

Keywords: hyperuricemia, allopurinol, uric acid, gut microbiota, gut inflammation, intestinal barrier, AhR, IL-22, tryptophan metabolism, indole, IDO1, high-fat diet